Stockscreener 앱 받기
0.9188
7.18%
-0.0711
시간 외 거래:
.92
0.0012
+0.13%
Lakeshore Biopharma Co Ltd 주식(LSB)의 최신 뉴스
Comparing Fulcrum Therapeutics (NASDAQ:FULC) and Lakeshore Biopharma (NASDAQ:LSB) - Defense World
LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - marketscreener.com
Lakeshore Biopharma Dave Chenn Resigned As Chairman - marketscreener.com
LakeShore Biopharma Announces Leadership Change with New Chairman Appointment - TipRanks
LakeShore Biopharma Enters Financing Lease Agreement for RMB110 Million - TipRanks
LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell) - The Manila Times
Revolutionary Needle-Free Technology Transforms Rabies Vaccine Delivery: China's First Smart Packaging Solution - Stock Titan
TuHURA Biosciences (NASDAQ:HURA) vs. Lakeshore Biopharma (NASDAQ:LSB) Head-To-Head Contrast - Defense World
LakeShore Biopharma Announces Court Dismissal Of Former Chairman's Injunction Applications - MarketScreener
LakeShore Biopharma Adopts Amended Share Incentive Plan - TipRanks
YS Biopharma Shares Surge 18% Pre-Bell on Estimated Preliminary Revenue for Fiscal Year 2023 - Marketscreener.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Revenues Working Against LakeShore Biopharma Co., Ltd's (NASDAQ:LSB) Share Price Following 27% Dive - Simply Wall St
LakeShore Biopharma : Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full Year Guidance Form 6 K - Marketscreener.com
LakeShore Biopharma Posts First Profit Since 2013, Revenue Soars 36% in Strong H1 Earnings - StockTitan
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance - Finansavisen
LakeShore Biopharma provides update on ongoing investigation involving Yi Zhang - TipRanks
LakeShore Biopharma Pursues Criminal Investigation Against Ex-Chairman for Major Corporate Fraud - StockTitan
LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China - GlobeNewswire
Omeros Corp (OMER) Stock Surges Amidst Biotech Sector Activity - GuruFocus.com
LakeShore Biopharma Initiates Biologics License Application - GlobeNewswire
LakeShore Biopharma Co., Ltd Provides Financial Guidance for the Half Year of Fiscal Year of 2025 and Full Year of Fiscal Year 2025 Ending on March 31, 2025 - marketscreener.com
Investors Don't See Light At End Of LakeShore Biopharma Co., Ltd's (NASDAQ:LSB) Tunnel And Push Stock Down 66% - Simply Wall St
LakeShore Biopharma regains Nasdaq compliance - Investing.com
LakeShore Biopharma Advances with Rabies Vaccine Trial - Yahoo Finance
LakeShore Biopharma’s YSJA Rabies Vaccine Heads to Phase III Trial - Contract Pharma
YS Biopharma (YSB) Stock Price, News & Analysis - MarketBeat
LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance - 팜뉴스
LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation - PR Newswire
Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024 - StockTitan
LakeShore changes CEO with new executive appointments - The Pharma Letter
LakeShore Biopharma Announces Leadership Transitions - PR Newswire
YS Biopharma COVID-19 Vaccine Candidate Against Omicron Variant Meets Primary, Secondary Goals - Marketscreener.com
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024 - PR Newswire
LakeShore Biopharma Insider Ups Holding By 3,083% During Year - simplywall.st
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition - PR Newswire
LakeShore Biopharma Co., Ltd (NASDAQ:LSB): When Will It Breakeven? - Yahoo Finance
LSB Stock Price and Chart — NASDAQ:LSB - TradingView
YS Biopharma Co., Ltd. will Change its Ticker to LSB from YS - Marketscreener.com
YS Biopharma Announces Name Change to LakeShore Biopharma - Nasdaq
YS Biopharma Announces Results of Extraordinary General Meeting - PR Newswire
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer - PR Newswire
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - PR Newswire
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine - PR Newswire
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries - PR Newswire
YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024 - PR Newswire
YS Biopharma Announces Appointment of New Directors - PR Newswire
YS Biopharma Announces US$40 Million Private Placement Financing - PR Newswire
YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting - Marketscreener.com
Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target - PR Newswire
YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023 - Marketscreener.com
YSYS Biopharma Co., Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
1.91%
1.17%
자본화:
|
볼륨(24시간):